# Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland

> **NCT05701007** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1083 (actual)

## Conditions studied

- Metastatic Castration Sensitive Prostate Cancer (mCSPC)
- Metastatic Castration Resistant Prostate Cancer (mCRPC)

## Interventions

- **DRUG:** abiraterone
- **DRUG:** enzalutamide
- **DRUG:** docetaxel
- **DRUG:** apalutamide
- **DRUG:** cabazitaxel
- **DRUG:** Radium-223
- **DRUG:** Lutetium-177
- **DRUG:** degarelix
- **DRUG:** goserelin
- **DRUG:** leuprorelin
- **DRUG:** triptorelin

## Key facts

- **NCT ID:** NCT05701007
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-13
- **Primary completion:** 2024-04-10
- **Final completion:** 2024-04-10
- **Target enrollment:** 1083 (ACTUAL)
- **Last updated:** 2026-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05701007

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05701007, "Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05701007. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*